-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hengrui Medicine issued an announcement stating that it received a notice from the US Food and Drug Administration (FDA) that the company's application for a short new drug for injection of carmustine has been approved, and the drug can be produced and sold in the US market.
In this regard, the industry believes that this marks the new results of Hengrui Pharmaceutical's preparation and will have a positive impact on the company's expansion in the US market.
In this regard, the industry believes that this marks the new results of Hengrui Pharmaceutical's preparation and will have a positive impact on the company's expansion in the US market.
In fact, as far as the author knows, up to now, Hengrui Medicine has approved 20 products, including injections, oral preparations and inhaled anesthetics, for sale in Europe, America and Japan.
According to the previous 2020 Pharmaceutical Innovation Index and Pharmaceutical Invention Index rankings released by the British medical information company IDEA Pharma, Hengrui Pharmaceuticals is ranked 13th and 15th respectively on the list for the first time.
The innovative strength of Hengrui Pharmaceuticals is It is in the forefront, and the new medicine is also accelerating.
According to the previous 2020 Pharmaceutical Innovation Index and Pharmaceutical Invention Index rankings released by the British medical information company IDEA Pharma, Hengrui Pharmaceuticals is ranked 13th and 15th respectively on the list for the first time.
The innovative strength of Hengrui Pharmaceuticals is It is in the forefront, and the new medicine is also accelerating.
In recent years, in fact, with the implementation of major national science and technology projects for major new drug creation in my country, the domestic new drug creation pattern has gradually begun to change.
With continuous breakthroughs in a number of key drug creation technologies and production processes, my country’s independent research and development of innovative drugs have successively appeared on the stage.
Appeared; At the same time, the layout of domestic medicine has also begun to accelerate.
With continuous breakthroughs in a number of key drug creation technologies and production processes, my country’s independent research and development of innovative drugs have successively appeared on the stage.
Appeared; At the same time, the layout of domestic medicine has also begun to accelerate.
It is understood that in recent years, many innovative pharmaceutical companies have obtained the U.
S.
FDA breakthrough therapy designation, orphan drug designation, and fast track review qualifications.
Among them, companies such as BeiGene, Yasheng Pharmaceutical, Rongchang Biological, and CStone Pharmaceuticals have even become models for domestic innovative pharmaceutical companies to enter overseas.
S.
FDA breakthrough therapy designation, orphan drug designation, and fast track review qualifications.
Among them, companies such as BeiGene, Yasheng Pharmaceutical, Rongchang Biological, and CStone Pharmaceuticals have even become models for domestic innovative pharmaceutical companies to enter overseas.
For example, BeiGene submitted a new drug application for Zebutinib in Europe and Israel last year.
This new anti-cancer drug, which is completely independently developed by Chinese companies and approved for listing by the FDA in the United States, has achieved the goal of China's original anti-cancer drug going overseas.
breakthrough.
This new anti-cancer drug, which is completely independently developed by Chinese companies and approved for listing by the FDA in the United States, has achieved the goal of China's original anti-cancer drug going overseas.
breakthrough.
There is also a new ADC drug RC48 (trade name: Aidixi) independently developed by Rongchang Biopharmaceuticals.
It was also approved by the U.
S.
Food and Drug Administration (FDA) in the first half of last year and was allowed to directly conduct Phase II clinical trials in the United States.
The card is HER2-positive locally advanced or metastatic urothelial carcinoma.
It is reported that RC48 is Rongchang Bio's second new drug approved for clinical trials in the United States, and is an important milestone in Rongchang Bio's development.
It was also approved by the U.
S.
Food and Drug Administration (FDA) in the first half of last year and was allowed to directly conduct Phase II clinical trials in the United States.
The card is HER2-positive locally advanced or metastatic urothelial carcinoma.
It is reported that RC48 is Rongchang Bio's second new drug approved for clinical trials in the United States, and is an important milestone in Rongchang Bio's development.
In addition, CSPC's performance in expanding overseas markets in recent years has also been very impressive.
As early as December 2019, it announced that the U.
S.
FDA has approved a new drug application (NDA) for the treatment of hypertension with levoamlodipine maleate tablets (trade name: Xuan Ning).
Not only has it become the first Chinese local innovative drug to be fully approved by the FDA, it also means that the product has obtained a marketing license.
In addition, CSPC is still going global through various forms, including product mergers and acquisitions, and technology transfer.
As early as December 2019, it announced that the U.
S.
FDA has approved a new drug application (NDA) for the treatment of hypertension with levoamlodipine maleate tablets (trade name: Xuan Ning).
Not only has it become the first Chinese local innovative drug to be fully approved by the FDA, it also means that the product has obtained a marketing license.
In addition, CSPC is still going global through various forms, including product mergers and acquisitions, and technology transfer.
In general, with the continuous advancement of policies such as medical insurance control fees and volume purchases, the concentration of domestic industries is continuously increasing, and the pharmaceutical landscape has changed significantly.
In order to obtain more profits, more and more domestic pharmaceutical companies have also begun to accelerate the road of layout.
The industry predicts that under this background, more pharmaceutical companies may introduce overseas technologies and resources into the country through expansion, combine the applications in the local market, and then seek overseas market expansion.
In the future, the chemical capability of domestic drugs will be further improved.
In order to obtain more profits, more and more domestic pharmaceutical companies have also begun to accelerate the road of layout.
The industry predicts that under this background, more pharmaceutical companies may introduce overseas technologies and resources into the country through expansion, combine the applications in the local market, and then seek overseas market expansion.
In the future, the chemical capability of domestic drugs will be further improved.
